Cohance Lifesciences Limited has scheduled its eighth Annual General Meeting (AGM) for September 17, 2026. The event will be conducted through video conference or other audio-visual means.

The meeting aims to transact ordinary business items for the financial year ended March 31, 2026. Key agenda points include the adoption of standalone and consolidated financial statements. Shareholders will also vote on the reappointment of Ms. Shweta Jalan as a director liable to retire by rotation.

Meeting Schedule and Logistics

The AGM will commence at 4:00 pm on Thursday, September 17, 2026. The company has engaged KFin Technologies Limited to facilitate the remote e-voting process. Members holding shares as on the cut-off date of September 10, 2026, are eligible to vote.

Director Reappointment Details

Ms. Shweta Jalan, who brings over 25 years of experience in private equity, offers herself for reappointment. She currently serves as a Managing Partner at Advent and joined the board in November 2023. Her remuneration for this role is nil.

Ms. Jalan attended nine out of eleven board meetings held during FY26. She holds directorships in Svatantra Microfin Private Limited, Modenik Lifestyle Private Limited, and Coforge Limited. She resigned from Yes Bank Limited within the past three years.

Cohance Lifesciences Limited reported a consolidated net loss of 241M rupees in Q1FY27, narrowing significantly from a net loss of 489M rupees in the corresponding period of the previous year. The decline in revenue from operations to 4.22B rupees from 5.5B rupees year-on-year was primarily attributed to shipment phasing in the Pharma Contract Development and Manufacturing Organization (CDMO) segment and softer contributions from agrochemicals. Despite the low base, management highlighted tangible indicators of progress, including secured restocking orders for commercial molecules and scheduled deliveries for recently commercialized programs, projecting sequential improvement in Q2FY27 and a return to year-on-year growth from the second half of the fiscal year.

The Board of Directors approved the unaudited financial results on August 5, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker Chandiok & Co LLP issued an unmodified limited review report. CFO Himanshu Agarwal confirmed his tenure will continue until September 13, 2026, after which the company will update stakeholders on the succession process.

Financial Performance Highlights

On a standalone basis, net profit fell 97.3% year-on-year to ₹14 crore, while standalone revenue from operations declined 25.6% to ₹359.89 crore. Consolidated gross margins contracted to 71.5% from 73.0% in Q1FY26, driven by product mix shifts and higher freight costs. The consolidated adjusted EBITDA stood at INR92 million (margin of 2.2%), down from higher levels in the prior year, reflecting negative operating leverage and losses from subsidiaries.

Segment Updates and Strategic Initiatives

In the Pharma CDMO segment, revenue declined 38.7% year-on-year due to shipment timing. However, two molecules have moved into commercial supply with deliveries scheduled across Q2FY27 and Q3FY27. A significant restocking order for a commercial molecule affected by inventory destocking in FY26 has been secured, providing visibility for Q4 FY27 and FY28. The API+ segment remained resilient despite a 10.4% year-on-year revenue decline, supported by favorable pricing and product mix. Specialty Chemicals revenue declined 34.7% year-on-year, largely due to expected second-half-weighted phasing in Agrochemicals.

Management announced strategic realignments, including building an integrated nucleic-acid business through Sapala Organics Private Limited. Dr. P.Y. Reddy has agreed to lead this combined nucleic acid business through FY30. Sapala reported 2.5x revenue growth in Q1FY27, contributing INR274 million to consolidated revenue. Conversely, NJ Bio reported an adjusted EBITDA loss of INR328 million, weighing heavily on consolidated profitability.

What the Numbers Show

The divergence between standalone and consolidated performance underscores the transitional challenges following recent acquisitions. While the core standalone business maintained a positive adjusted EBITDA margin of 9.2%, the consolidated entity absorbed significant losses from subsidiaries, particularly NJ Bio. The company maintains a strong liquidity position with consolidated net cash of approximately ₹2,512 million as of June 30, 2026, supporting capital expenditure plans of ₹598 million during the quarter. Additionally, the USFDA completed an inspection of the Pashamylaram facility from July 27 to August 5, 2026, issuing a Form 483 with five observations, none relating to data integrity.